Zacks Investment Research on MSN
Ocugen's gene-agnostic eye therapies could reshape late-stage care
Ocugen OCGN is advancing a retinal pipeline built around durability and breadth. Its focus is a modifier gene therapy ...
Morning Overview on MSN
A gene therapy injected straight into brain tumors just began dosing its first patients — a virus engineered to kill glioblastoma cells and spare the rest
Somewhere in an operating room this spring, a neurosurgeon did something that has never been done before: while removing a patient’s brain tumor, the surgical team threaded a thin cannula into the ...
The FDA must provide consistent and predictable regulatory frameworks if the U.S. is to maintain its leadership in gene ...
A research team at the University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene therapy. The study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results